Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
NCT02269592 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2026-05-07
Summary
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered.
Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study.
This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA
Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Myelodysplastic Syndromes
- Hematological Malignancies
- B-cell Malignancy, Low-grade
- Myelodysplastic Syndrome With Low-grade Lesions
- IgG Monoclonal Gammopathy of Uncertain Significance
- Smoldering Multiple Myeloma
- Waldenstrom Macroglobulinemia
Sponsors & Collaborators
-
The Leukemia and Lymphoma Society
collaborator OTHER - lead OTHER
Principal Investigators
-
Irene Ghobrial, MD · Dana-Farber Cancer Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-08-31
- Primary Completion
- 2027-12-31
- Completion
- 2030-09-30
Countries
- United States
Study Locations
More Related Trials
-
Pathogenesis of Hematologic Malignancies
NCT01728402 ·Status: ENROLLING_BY_INVITATION
-
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
NCT04060485 ·Status: UNKNOWN
-
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
NCT01079429 ·Status: TERMINATED
-
S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia
NCT01434329 ·Status: COMPLETED
-
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
NCT04298892 ·Status: UNKNOWN
-
Biology and Genetics of Smouldering Myeloma
NCT05047107 ·Status: UNKNOWN
-
Familial Investigations of Childhood Cancer Predisposition
NCT03050268 ·Status: RECRUITING
-
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
NCT00981097 ·Status: COMPLETED
-
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
NCT01454297 ·Status: COMPLETED
-
Biomarker for Infection Risk in CLL and MM
NCT05844033 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
NCT00039676 ·Status: ACTIVE_NOT_RECRUITING
-
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
NCT00339963 ·Status: COMPLETED
-
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
NCT05837884 ·Status: RECRUITING
-
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
NCT05588154 ·Status: RECRUITING
-
Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia
NCT01016379 ·Status: COMPLETED
-
Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia
NCT02330718 ·Status: UNKNOWN
-
Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01057095 ·Status: COMPLETED
-
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
NCT05758948 ·Status: UNKNOWN
-
S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
NCT01563861 ·Status: COMPLETED
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·Status: RECRUITING
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
NCT06736613 ·Status: RECRUITING ·Phase: PHASE2
-
MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank
NCT02537990 ·Status: UNKNOWN
-
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients
NCT03079947 ·Status: UNKNOWN
-
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT02279004 ·Status: ACTIVE_NOT_RECRUITING
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
NCT00131014 ·Status: RECRUITING